Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Trial Profile

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs LCAR-B38M CAR-T cell therapy (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms LEGEND-2
  • Sponsors Nanjing Legend Biotech
  • Most Recent Events

    • 03 Dec 2018 Results (n=57) published in a Janssen media release.
    • 03 Dec 2018 According to a Janssen media release, data were presented at the 60th American Society of Hematology (ASH) Annual Meeting.
    • 23 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top